Type 2 diabetes landscape during COVID-19
MISSISSAUGA, ON, Sept. 10, 2020 /CNW/ – 551 Canadians, aged 18 to 80 diagnosed with type 2 diabetes, were surveyed between May 20 – May 26, 2020 with representation from every province. The margin of error is +/- 2.5%, 19 times out of 20. The online survey was supported by Novo Nordisk Canada Inc. and completed via Maru/Blue’s online consumer panel.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 43,500 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.ca, Twitter, or YouTube.
SOURCE Novo Nordisk Canada Inc.